Ethan Magid

Profil Ethan Magid

Ethan was promoted to Counsel in our global transactions group in 2022 and is qualified in both New York and England & Wales.

Having started his legal career at Freshfields in 2013, Ethan has developed a strong reputation with clients and is increasingly well-connected and prominent in his field. His practice focuses on representing issuers, sponsors and underwriters in connection with equity and debt capital markets transactions, and he has experience advising on transactions in the UK, Europe, Middle East and Africa. He takes lead roles on high-profile mandates, including the recent IPOs of CVC Capital Partners, Zabka and Parkin.

Ethan also advises on US and UK capital markets aspects of significant cross-border M&A transactions, including advising AstraZeneca on its collaboration and investment agreement with Cellectis and its $39 billion acquisition of Alexion, and Rentokil Initial on its $6.7 billion acquisition of Terminix. He also advises clients on a range of US SEC reporting obligations.

In 2017/18, Ethan was seconded to the Equity Capital Markets Execution team at a major US investment bank where he gained valuable commercial insight.

Within the firm, Ethan sits on the global steering committee of Freshfields’ LGBTQ+ network.

Mandate

Recent initial public offerings

• Advising Zabka and CVC on the 2024 IPO of Zabka on the Warsaw Stock Exchange
• Advising CVC Capital Partners on its 2024 IPO on Euronext Amsterdam
• Advising Parkin and the Emirate of Dubai on the 2024 IPO of Parkin on the Dubai Financial Market
• Advising HSBC on the 2023 IPO of SAL Saudi Logistics on the Saudi Exchange
• Advising Synsam and CVC on the 2021 IPO of Synsam on Nasdaq Stockholm
• Advising Goldman Sachs Asset Management and Petershill Partners on the 2021 London IPO of Petershill Partners
• Advising Allfunds and Hellman & Friedman on the 2021 IPO of Allfunds on Euronext Amsterdam

Recent follow-on equity offerings

• Advising DSV on its primary capital raise of c.€5 billion to partly finance its expected acquisition of Schenker AG
• Advising Lilium on its May 2024 and July 2023 capital raises through underwritten public offerings and concurrent private placements
• Advising CVC in connection with the sell-downs of Synsam shares in March 2024 and June 2022
• Advising HSBC and Morgan Stanley on the November 2022 sell-down of Tadawul shares by Saudi Arabia’s Public Investment Fund, raising approximately $613 million for PIF
• Advising Aston Martin Lagonda on its £654 million strategic placing and rights issue in 2022, its £125 million placing and strategic cooperation with Mercedes-Benz in 2020 and its £535 million placing and rights issue in 2020
• Advising Hellman & Friedman in connection with the September 2021 sell-down of Allfunds shares, raising approximately €880 million for the sellers

Recent M&A and other experience

• Advising AstraZeneca on its collaboration and investment agreement with Cellectis
• Advising Deliveroo on its buyback of £250 million of shares by way of a tender offer
• Advising Rentokil Initial on its $6.7 billion acquisition of Terminix
• Advising AstraZeneca on its $39 billion acquisition of Alexion